Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) CMO Joanne M. Donovan sold 3,682 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $69,626.62. Following the completion of the sale, the chief marketing officer now owns 19,897 shares in the company, valued at approximately $376,252.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Edgewise Therapeutics Trading Up 1.2 %
Shares of NASDAQ:EWTX opened at $19.52 on Friday. Edgewise Therapeutics, Inc. has a 12 month low of $5.12 and a 12 month high of $20.90. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -12.35 and a beta of 0.15. The firm’s 50-day moving average is $16.90 and its 200 day moving average is $12.73.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last released its earnings results on Thursday, February 22nd. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). As a group, equities analysts forecast that Edgewise Therapeutics, Inc. will post -1.76 EPS for the current fiscal year.
Hedge Funds Weigh In On Edgewise Therapeutics
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. Piper Sandler started coverage on shares of Edgewise Therapeutics in a report on Thursday, March 7th. They issued an “overweight” rating and a $48.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $26.00 price objective on shares of Edgewise Therapeutics in a research note on Tuesday, April 16th. Truist Financial restated a “buy” rating and set a $25.00 price objective on shares of Edgewise Therapeutics in a research report on Wednesday, April 17th. Finally, Royal Bank of Canada lifted their target price on Edgewise Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, April 22nd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.20.
Check Out Our Latest Stock Analysis on Edgewise Therapeutics
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Further Reading
- Five stocks we like better than Edgewise Therapeutics
- How Technical Indicators Can Help You Find Oversold Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- 3 Healthcare Dividend Stocks to Buy
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Transportation Stocks Investing
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.